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Upregulated RIP3 Expression Potentiates MLKL
Phosphorylation–Mediated Programmed Necrosis in
Toxic Epidermal Necrolysis
Sue Kyung Kim1,6, Woo-Jung Kim2,3,6, Jung-Ho Yoon2,3, Jae-Hoon Ji4, Michael J. Morgan5, Hyeseong Cho2,3,
You Chan Kim1 and You-Sun Kim2,3
Toxic epidermal necrolysis (TEN) is a severe adverse drug reaction involving extensive keratinocyte death in the
epidermis. Histologically, the skin from TEN patients exhibits separation at the dermo–epidermal junction and
accompanying necrosis of epidermal keratinocytes. Receptor-interacting protein kinase-3 (RIP3 or RIPK3) is an
essential part of the cellular machinery that executes “programmed”, or “regulated”, necrosis and has a key role
in spontaneous cell death and inﬂammation in keratinocytes under certain conditions. Here we show that RIP3
expression is highly upregulated in skin sections from TEN patients and may therefore contribute to the
pathological damage in TEN through activation of programmed necrotic cell death. The expression level of mixed
lineage kinase domain-like protein (MLKL), a key downstream component of RIP3, was not signiﬁcantly different
in skin lesions of TEN. However, elevated MLKL phosphorylation was observed in the skin from TEN patients,
indicating the presence of RIP3-dependent programmed necrosis. Importantly, in an in vitro model of TEN,
dabrafenib, an inhibitor of RIP3, prevented RIP3-mediated MLKL phosphorylation and decreased cell death.
Results from this study suggest that the high expression of RIP3 in keratinocytes from TEN patients potentiates
MLKL phosphorylation/activation and necrotic cell death. Thus, RIP3 represents a potential target for treatment
of TEN.
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INTRODUCTION
Toxic epidermal necrolysis (TEN) is a blistering disease most
commonly caused by inappropriate immune activation in
response to drugs. TEN is characterized by marked epidermal
keratinocyte cell death with separation at the dermo–
epidermal junction and lesions that show evidence of necrosis
(Pereira et al., 2007). Although rare, it has a mortality rate of
30% (Ghislain and Roujeau, 2002). TEN occurs in all ages but
is more commonly seen in the immunosuppressed (Downey
et al., 2012). The pathophysiology is not well known,
although immune mechanisms and altered drug metabolism
are potentially responsible (Downey et al., 2012). An
association between the antiepileptic drug carbamazepine
and major histocompatibility complex I allotype HLA-B*1502
exists in some races with TEN, (Man et al., 2007; Mehta et al.,
2009; Chang et al., 2011; Wei et al., 2012), but not in others
(Kaniwa et al., 2008; Kim et al., 2011), suggesting that genetic
factors may predispose to TEN.
Little is known about the precise molecular events leading
to the epidermal necrolysis observed in TEN, but FasL-
mediated cell death and reactive oxygen species (ROS) have
been implicated (Abe, 2008; Murata et al., 2008). Epidermal
tumor necrosis factor-α (TNF-α) found in TEN patients may
contribute to ROS generation through stimulation of nitric
oxide production (Kroncke et al., 1997). Other reports suggest
that keratinocyte death in TEN lesions is induced by
granulysin exocytosed from CD8 T cells or natural killer
cells (Chung et al., 2008). When cellular FLICE-inhibitory
protein expression is abrogated in the skin, severe cutaneous
inﬂammation with cell death develops (Panayotova-
Dimitrova et al., 2013), suggesting that cellular FLICE-
inhibitory protein levels may be relevant in TEN.
Programmed necrosis is activated in response to death
receptor ligands and other cellular stressors (Declercq et al.,
2009; Vandenabeele et al., 2010; Vanlangenakker et al., 2012b).
Programmed or “regulated” necrotic cell death is different
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from apoptosis in that caspases are not essential for cell death
to occur, but necrotic events lead to membrane permeability
and cell lysis (Galluzzi et al., 2012). Inhibition of this pathway
is essential for proper mammalian development (Kaiser et al.,
2011; Oberst et al., 2011; Zhang et al., 2011) and prevents
spontaneous cell death and inﬂammation in keratinocytes
(Kovalenko et al., 2009; Bonnet et al., 2011). (The use of the
terms “programmed necrotic cell death” or “programmed
necrosis” are used herein in a wider context than develop-
ment, designating all death that occurs using the speciﬁc
necrotic cell machinery for this kind of death. Others use
these terms in a more restrictive manner, designating only
normal developmental cell death).
The programmed necrotic pathway includes the formation of
a “necrosome” or a “Ripoptosome” complex containing
receptor-interacting protein kinases RIP3(RIPK3) and RIP1
(RIPK1) and recruitment of mixed lineage kinase domain-like
protein (MLKL; Sun et al., 2012; Zhao et al., 2012). The
Ripoptosome complex is relevant to cell death pathways in
keratinocytes, and its activity is regulated by cIAP proteins and
cellular FLICE-inhibitory protein isoforms (Feoktistova et al.,
2011). RIP3-dependent phosphorylation and plasma membrane
localization of MLKL is necessary for programmed necrotic cell
death and leads to membrane permeabilization and cell death
(Cai et al., 2014; Chen et al., 2014). Marion et al. reported
sensitization of keratinocytes to RIP3-mediated necrosis as a
potent mechanism triggering skin inﬂammation and proposed
that factors sensitizing keratinocytes to programmed necrosis
could contribute to inﬂammatory skin diseases and chronic
inﬂammation (Bonnet et al., 2013). Several reports suggest that
high expression of RIP3 functions in inﬂammatory disease
pathogenesis (Wu et al., 2012; Pierdomenico et al., 2014).
Here we show that RIP3 protein expression is highly elevated
in TEN and may therefore contribute to cytotoxicity in TEN
keratinocytes through potentiation of programmed necrotic cell
death. We found elevated levels of phosphorylated MLKL in
TEN lesions, suggesting that programmed necrosis is active. As
RIP3 expression regulates the sensitivity of keratinocytes to
necrotic stimuli, we propose that high RIP3 expression may
contribute to TEN pathology and RIP3 could represent potential
drug target for the management of TEN in patients.
RESULTS
RIP3 expression is substantially increased in TEN lesions
We analyzed RIP3 protein expression in the skin tissue from
TEN patients with marked epidermal keratinocyte cell death.
The TEN patients exhibited multiple erythematous macules
evolving to bullae and epidermal detachment on the trunk
(Figure 1a). Figure 1b shows clinical characteristics and
laboratory results from our TEN patients (n=10), including
age, heart rate, affected body surface area, and serum glucose
levels, all of which are important prognostic factors for TEN
patients. C-reactive protein levels, which rapidly rise in
response to inﬂammation, were positively correlated with
RIP3 expression in the lesional skin of TEN patients, as
measured by immunohistochemistry (Figure 1b, right). This
makes sense given that programmed necrosis can trigger
inﬂammation (Kaczmarek et al., 2013). Normal skin exhibited
intact epidermis, but lesional skin from TEN showed
eosinophilic necrosis of the epidermis, with some detachment
from the dermis (Figure 1c and d). Comparable immuno-
histochemistry sections showed a signiﬁcant increase in RIP3
expression levels when compared with normal skin. Quanti-
ﬁcation using an image analysis program indicated that RIP3
expression in the epidermal area (pigmented area per
measured epidermal area) was signiﬁcantly increased in the
TEN skin compared with normal skin (Figure 1c and d).
In contrast to RIP3, expression of the downstream effector
MLKL was not statistically different in TEN skin compared
with normal skin (Figure 1e). Antibody speciﬁcity of the RIP3
and MLKL antibodies was conﬁrmed by overexpression or
knockdown of these two proteins, respectively, in several
types of cells (Supplementary Figures S1A–C, S2A online).
In addition, antibodies against GP100, which is commonly
used to detect epidermal melanocytes, and Ki-67, which
normally is an indicator of cell proliferation, stained
similarly in normal skin and TEN lesions (Supplementary
Figure S2B online), indicating that the detected RIP3
differences were not due to general issues with staining of
the TEN lesion samples.
Canonical programmed necrosis can be executed in skin cells
As high expression of RIP3 could have a role in necrolysis in
TEN patients, we ﬁrst investigated whether skin cells were
capable of executing programmed necrosis. All skin cell types
examined, including primary melanocytes, ﬁbroblasts, and
keratinocytes, expressed RIP3 (Supplementary Figure S3A
online). The immortal human keratinocyte line HaCaT and
primary human epidermal keratinocyte (HEKn) isolated from
neonatal foreskin responded to prototypical programmed
necrotic stimuli (Supplementary Figure S3B online) induced
by TNF-α (TNF-α+zVAD+either cycloheximide or SMAC
mimetic, also referred to herein as TCZ or TSZ). Inhibition of
caspase activity by zVAD completely blocked caspase-3 and
PARP processing (data not shown), but did not prevent TNF-
induced cell death, indicating that RIP3-expressing keratino-
cytes are capable of dying by prototypical programmed
necrosis, similar to what is observed in the human colon
adenocarcinoma HT-29 cell line (Supplementary Figure S3C
online), which is a standard model for the study of pro-
grammed necrosis. As expected, RIP3 (and RIP1) knockout
mouse embryonic ﬁbroblasts were resistant to TNF-induced
necrotic cell death conditions (Supplementary Figure S4A
online), consistent with the roles of these proteins in
programmed necrosis. Similarly, knockdown of RIP3 effec-
tively reduced TNF-induced necrotic cell death in human
dermal ﬁbroblast and HaCaT cells, indicating that RIP3 is
essential for programmed necrosis in skin cells (Supple-
mentary Figure S4B online). Thus, the canonical programmed
necrotic pathway can be executed in skin cells.
SNP-induced keratinocyte cell death is accompanied by
RIP3-dependent programmed necrosis
Lesional skin of TEN patients is characterized by high levels of
inducible nitric oxide synthase and associated nitric oxide
(NO) production and is believed to contribute to TEN
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pathology (Schwartz et al., 2013). Previous studies have
employed sodium nitroprusside (SNP), an NO donor, as a
model agent (Viard-Leveugle et al., 2013). As SNP does not
induce RIP3 expression (or TNF-α) (Supplementary Figure S5
online), this suggests that induction of RIP3 occurs upstream
and independently of NO production in TEN and that SNP
could be used to look at the downstream consequences of
NO production in TEN after RIP3 has been highly expressed.
SNP treatment of HaCaT and HEKn cells induced dose-
dependent cell death (Figure 2a; Supplementary Figure S6A
online) and phosphorylation of mitogen-activated protein
kinase (Figure 2b). The pancaspase inhibitor zVAD had only a
small effect on SNP-induced cell death, although it com-
pletely blocked caspase-3 and PARP processing induced by
TNF/CHX and SNP (Supplementary Figure S6B online). SNP-
induced cell death was more substantially decreased in the
presence of necrostatin-1 (Nec-1), an inhibitor of RIPK1 and
programmed necrosis (Degterev et al., 2008); the further
combination of zVAD and Nec-1 had a more pronounced
inhibitory effect upon SNP-induced cell death (Figure 2c, top),
suggesting that SNP activates both apoptosis and programmed
necrosis. Phase-contrast microscopy and annexin-V staining
as monitored by ﬂow cytometry in HaCaT cells likewise
indicated that SNP-induced cell death was inhibited by these
compounds, with Nec-1 being more potent (Figure 2c,
bottom). We therefore also tested other pharmacological
inhibitors of programmed necrosis–dabrafenib, which inhibits
RIP3 kinase activity (Li et al., 2014a), and necrosulfonamide,
which inhibits MLKL functions downstream of RIP3
phosphorylation (Wang et al., 2014). All three inhibitors
were substantially better at protecting HEKn cells from the
acute SNP cytotoxicity than zVAD, which had little effect
(Figure 2d; Supplementary Figure S6C online).
RIP3 and RIP1 potentiate SNP-induced keratinocyte cell death
RIP3 knockout mouse embryonic ﬁbroblasts ectopically
expressing RIP3 became more sensitive to SNP-mediated cell
death (Supplementary Figure S7A online), whereas knock-
down of RIP3 in HaCaT, primary keratinocytes (HEKn), or
human dermal ﬁbroblasts inhibited SNP-induced cell death
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Figure 1. Upregulation of receptor-interacting protein kinase-3 (RIP-3) in TEN lesions. (a) Photograph of a TEN patient showing conﬂuent and erythematous
macules and patches with ﬂaccid bullae and epidermal detachment. (b) Left: clinical characteristics and laboratory results for TEN patients (n=10). Right: RIP3
expression in lesional skin is positively correlated with plasma CRP levels in TEN patients. (c-d) Left: immunohistochemical staining indicates that RIP3 expression
is increased in TEN skin compared with normal skin. H&E staining shows lesional skin of TEN with eosinophilic epidermal necrosis and separation of dermo–
epidermal junction, whereas normal skin is intact. Right: quantitative image analysis of RIP3 staining. (e) Immunohistochemical staining and quantitative image
analysis showing that expression of MLKL in TEN lesional skin is not signiﬁcantly different than normal skin (black scale bar=100 μm). CRP, C-reactive protein;
H&E, hematoxylin and eosin; MLKL, mixed lineage kinase domain-like protein; PA/EA, pigmented area per measured epidermal area; TEM, toxic epidermal
necrolysis.
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(Supplementary Figure S7B online; Figure 3a and b).
Consistent with Nec-1 inhibition, RIP-1 knockdown inhibited
SNP-induced cell death in the HaCaT cells (Supplementary
Figure S7C online), further suggesting that RIP1/RIP3-depen-
dent programmed necrosis contributes to SNP-induced
cell death.
Sustained activation of the stress kinases c-Jun N-terminal
kinase (JNK) and p38 is often associated with programmed
necrosis and is essential for cell death in some cell types
(Ventura et al., 2004; Kim et al., 2007). Sustained SNP-induced
JNK and p38 activation, but not ERK (extracellular signal–
regulated kinase) activation, was inhibited in RIP3 knockdown
cells (Figure 3c); however, under non-necrotic conditions (i.e.,
no zVAD/CHX), TNF-induced JNK and p38 activation remained
relatively normal in the absence of RIP3 (Supplementary Figure
S7D online), consistent with their sustained activation down-
stream of RIP3 during programmed necrosis.
In order to examine the functional consequence of high
RIP3 expression in TEN, we ectopically expressed RIP3 in
HaCaT and HEKn cells (Figure 4a). Cells overexpressing RIP3
were more sensitive to SNP, especially after 6 hours
(Figure 4b), indicating that high expression of RIP3 is sufﬁcient
to promote SNP sensitivity. Thus, high expression of RIP3 in
TEN may potentiate the pathological process by sensitizing to
necrotic stimuli.
We (and others) have previously shown that, in some cases,
the induction of ROS and sustained JNK activation can
contribute to necrotic cell death (Kim et al., 2007; Wu et al.,
2011). In the RIP3-overexpressing cells, TNF-induced JNK
activation remained relatively normal under non-necrotic
conditions (i.e., no zVAD/CHX), but sustained activation of
JNK was potentiated upon a necrotic stimulus (TCZ;
Supplementary Figure S8A and B online). Likewise, activation
of JNK and p38 by SNP was potentiated in RIP3-expressing
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Figure 2. Programmed necrosis inhibitors reduce sodium nitroprusside (SNP)-induced keratinocyte cell death. (a) The MTT assay showing viability of HaCaT
and HEKn cells treated with indicated concentrations of SNP (24 hours). (b) Western blots showing mitogen-activated protein kinase activation in HaCaT and
HEKn cells in response to SNP (5 mM) for indicated time points. (c) The MTT assay (left panel) and phase-contrast microscopy (right panel) showing cells
pretreated with Nec-1 (80 μM) or/and zVAD (20 μM) for 1 hour followed by SNP treatment. Bottom panel shows annexin-V staining measured by FACS analysis.
(d) Cells were pretreated with Nec-1 or/and zVAD (left panel) or dabrafenib (10 μM) or necrosulfonamide (NSA, 0.5 μM; right panel) for 1 hour followed by SNP
or TSZ treatment (24 hours) and cell viability analyzed by LDH release (left panel). The MTT assay (right panel) or phase-contrast microscopy (bottom panel).
All results are averages± SEM. *Po0.05, **Po0.01, and ***Po0.005. HEKn, human epidermal keratinocyte; LDH, lactate dehydrogenase.
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Figure 3. Depletion of receptor-interacting protein kinase-3 (RIP-3) inhibits sodium nitroprusside (SNP)-induced keratinocyte cell death. (a) HaCaT cells with
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cells (Figure 4c). As ROS inactivate JNK phosphatases, leading
to JNK activity (Kamata et al., 2005), we measured ROS pro-
duction in response to SNP. ROS production was markedly
increased in RIP3-overexpressing HaCaT cells (Figure 4d),
suggesting that high RIP3 expression contributes to ROS
generation and potentiates JNK activation during SNP-
induced cell death. Importantly, pretreatment of the cells
with the ROS scavenger N-acetylcysteine inhibited SNP-
induced cell death to a similar extent as Nec-1 (Supple-
mentary Figure S9A online), indicating that ROS contributes
to SNP-induced cell death. SNP-induced cell death was
inhibited by JNK, p38, and ERK inhibitors (Supplementary
Figure S9B online). Thus, increased RIP3 may lead to
increased ROS production, which may then activate JNK
and p38 activation, further potentiating cell death.
High RIP3 expression contributes to cell death through MLKL
activation
RIP3-dependent phosphorylation and subsequent plasma
membrane localization of MLKL is necessary for programmed
necrotic cell death (Cai et al., 2014; Chen et al., 2014).
Phosphorylated MLKL was detected in HEKn cells treated
with SNP (Figure 5a). Moreover, SNP-induced p-MLKL
localized at the plasma membrane, similar to TSZ
(Figure 5b). However, knockdown of RIP3 eliminated MLKL
phosphorylation (Figure 5c), indicating that it was RIP3
dependent. In HaCaT and HEKn cells highly expressing
RIP3, p-MLKL was observed in the absence of stimulus
(Figure 5d). However, p-MLKL was further potentiated by SNP
(Figure 5e) or TSZ (Supplementary Figure S10 online). In
early-stage cells treated with SNP, p-MLKL was shown in
punctate structures, similar to cells treated with TSZ
(Figure 5f), before its translocation to the cell membrane. In
RIP3-overexpressing HaCaT and HEKn cells treated with SNP,
p-MLKL largely co-localized with RIP3 (Figure 5g and h) in
these early-stage punctate bodies, similar to the pattern seen
with TSZ treatment.
The basal phosphorylation of MLKL in RIP3-overexpressing
cells, as well as SNP-induced p-MLKL, was eliminated by
RIP3 inhibition with dabrafenib (Figure 6a, top), which
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correlated with its effects on cell death (Figure 6a, bottom).
Consistent with its mechanism of inhibition during necrosis
downstream of phosphorylation, MLKL phosphorylation
induced by SNP was not inhibited by necrosulfonamide
(Data not shown), although it inhibited SNP-mediated cell
death. Signiﬁcantly, knockdown of MLKL in RIP3-HaCaT
reduced cell death by SNP (Figure 6b), indicating that MLKL
activation contributed to SNP-mediated cell death. Finally,
and most importantly, elevated phosphorylation of MLKL was
detected in the skin from TEN patients (Figure 6c), establishing
its activation during TEN.
DISCUSSION
Programmed necrosis has been identiﬁed as an important
mechanism underlying multiple physiological and pathologi-
cal processes (Vanlangenakker et al., 2012a; Kaczmarek
et al., 2013). We found that the RIP3 protein, a key regulator
of programmed necrosis, was signiﬁcantly increased in TEN
skin compared with normal skin. In addition, we found
elevated levels of phosphorylated MLKL in TEN samples,
suggesting that programmed necrosis is activated and that the
RIP3-MLKL pathway has an important role in TEN pathology.
Both TNF-α and inducible nitric oxide synthase, with
accompanying NO production, have been implicated in the
pathological process of TEN (Schwartz et al., 2013). We found
that skin cells, including keratinocytes, were sensitive to
programmed necrosis in response to TNF-α and SNP, an NO
donor. Previously, the NO donor SNP was reported to induce
caspase-dependent apoptosis through upregulation of FasL
(Schwartz et al., 2013). In our hands, SNP-induced cell death
was only partially blocked by treatment of the pan-caspase
inhibitor zVAD but was signiﬁcantly decreased by the
programmed necrosis inhibitors Nec-1, NSA, and dabrafenib
and decreased further by a combination of these inhibitors
and zVAD. Furthermore, knockdown of RIP3 or MLKL
resulted in inhibition of SNP-induced cell death. Thus, our
data indicate that SNP not only initiates caspase activation but
also induces programmed necrosis. Therefore, it is likely that
programmed necrosis mediated by TNF-α and NO, which are
found in abundance in TEN, is highly potentiated by the high
RIP3 levels that are also found in TEN, resulting in greater
cytotoxicity. As Fas ligand has been implicated in TEN (Abe,
2008; Murata et al., 2008), it is also likely that high RIP3 levels
may sensitize to this ligand, especially as a role for RIP1 in
caspase-independent CD95 signaling in keratinocytes has
been shown (Geserick et al., 2009).
Dabrafenib inhibits the kinase activity of RIP3 (Li et al.,
2014b), and we have shown here that it inhibits TNF-α and
SNP-induced programmed necrosis in keratinocytes and other
skin cells. If RIP3 is important in TEN, then dabrafenib, which
inhibits and is already FDA approved (as selective BRAF
inhibitor) for the treatment of metastatic melanoma, may
potentially be an effective drug for the treatment of TEN.
Although we were preparing this manuscript for publica-
tion, a work by Saito et al. (2014), was published that also
suggests that necroptosis may contribute to the pathogenesis
of TEN and the Stevens Johnson syndrome (SJS) . They
identiﬁed annexin A1 secreted by monocytes as an important
mediator of keratinocyte death in TEN/SJS and claim that
annexin A1 binds to formyl peptide receptor 1, the receptor
for annexin A1, and activates the necroptosis pathway
through the RIP1/RIP3 complex. Although not rigorously
analyzed on this point, their data does seem in agreement that
RIP3 is highly expressed in TEN compared with normal.
Furthermore, their data show that control skin/keratinocytes
do not respond to necrotic stimuli as well as SJS/TEN lesions/
keratinocytes do, consistent with our data showing that high
RIP3 expression in TEN keratinocytes potentiates cell death in
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Figure 6. Receptor-interacting protein kinase-3 (RIP-3)-mediated mixed lineage kinase domainlike protein (MLKL) activation contributes to keratinocyte cell
death. (a) Top panel: HaCaT cells were pretreated with dabrafenib (10 μM) for 1 hour and then treated with TSZ or SNP for 7 hours, and cell lysates were analyzed
by western blot. Bottom panel: other cells were further treated for 24 hours and viability analyzed by the MTT assay. Results are averages± SEM. (b) RIP3-
expressing HaCaT cells were infected with a lentivirus-encoding MLKL shRNAs or non-silencing control. After selection with puromycin, cells with stable shRNA
integration were analyzed by western blotting (left panel) or treated with SNP for 24 hours and viability analyzed by the MTT assay (right panel). Results are
averages± SEM. (c) Immunohistochemical staining of phospho-MLKL (1:100) in parafﬁn-embedded tissue specimens from TEN patients (black scale bar=50 μm).
*Po0.05, **Po0.01, and ***Po0.005. SNP, sodium nitroprusside; TEN, toxic epidermal necrolysis.
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response to such stimuli. If the conclusions of this study are
true, annexin A1 may be an important necrotic stimulus that is
potentiated by high RIP3 expression in TEN.
In summary, on the basis of our data, we suggest that
programmed necrosis mediated by RIP3-MLKL contributes to
the pathological state of the skin in TEN. Therefore, RIP3
could be a potential therapeutic target for the treatment
of TEN.
MATERIALS AND METHODS
Reagents
Recombinant TNF-α and zVAD were from R&D Systems
(Minneapolis, MN). Anti-phopho-JNK(44682G), anti-phospho-ERK
(9101S), anti-phospho-p38(4511), anti-ERK(4695), anti-p38(9212),
anti-PARP-1(9542S), and anti-caspase 3(9662) antibodies were from
Cell Signaling (Danvers, MA). Anti-JNK antibody was from Invitrogen
(Carlsbad, CA). Anti-RIP3(72106) and phospho-MLKL(187091) anti-
bodies were from Abcam (Cambridge, MA). Nec-1, LPS, and MLKL
(M6697) antibodies were purchased from Sigma-Aldrich (St. Louis,
MO). Anti-GP100(7006-1) antibody was from Monosan (Uden, the
Netherlands). Anti-Ki-67(15580) antibody was from Abcam. Necro-
sulfonamide and cycloheximide were from Calbiochem (Danvers,
MA). Dabrafenib was from Selleckchem (Houston, TX). SMAC
mimetic (LCL-161) was from Adooq Bioscience (Irvine, CA).
Patients
After obtaining informed written consent, we investigated 10 patients
with TEN, which was conﬁrmed clinically and pathologically, the
clinical data collected by review of medical record, retrospectively.
This study was approved by the institutional review board (IRB
number: MED-KSP-13-029).
Immunohistochemistry and image analysis
Punch skin biopsy specimens (3 mm) were taken from 10 TEN
patients. Five normal tissues from patients who had performed skin
biopsy for diagnosis of pigmentary disease were used as controls.
Parafﬁn-embedded tissue sections of 3-μm thickness were processed
for light microscopic examination. Immunohistochemistry was
performed using standard techniques using primary antibodies to
RIP3, MLKL, p-MLKL, GP-100, and Ki-67. Quantitative analysis of
immunohistochemical stains was performed using Image Pro Plus,
Version 4.5 (Media Cybertics, Silver Spring, MD) on a representative
area of each specimen. The ratio of stained area to the measured
epidermal area (pigmented area per measured epidermal area) was
measured in TEN skin lesions and normal skin.
Cell culture
All cells were cultured at 37 °C in 5% CO2. Primary human dermal
ﬁbroblasts were previously described (Palmetshofer et al, 1995).
Fibroblasts and HaCaT cells were cultured in DMEM supplemented
with 10% fetal bovine serum, 2mM glutamine, 100 Uml− 1
penicillin, and 100 μgml− 1 streptomycin. Primary normal human
keratinocyte was cultured as previously described (Pincelli et al.,
1994). Skin specimens obtained from repeat Caesarean section
deliveries and circumcisions were used for cultures and grown in
Epilife medium (Gibco BRL, Gaithersburg, MD) with human
keratinocyte growth supplement (Gibco). Cells at passage 3–10
were used for experiments. HEKn cells were from Gibco and
maintained according to the manufacturer’s instructions in Epilife
medium with human keratinocyte growth supplement. Cells at
passage 3–6 were used for experiments. HaCaT/HEKn cells stably
expressing RIP3 were created from cells infected with pLX303-hRIP3
lentiviral plasmid.
Cell viability assay
Representative images were taken by a phase-contrast microscope.
Cell viability was determined using tetrazolium dye colorimetric tests
(the MTT assay) read at 570 nm. Cell viability was also assessed by
double labeling of cells with 2 μM calcein-AM and 4 μM EthD-1.
Calcein-positive live cells and EthD-1-positive dead cells were
visualized using ﬂuorescence microscopy (Axiovert 200M, Zeiss,
Jena, Germany). Lactate dehydrogenase leakage was quantiﬁed using
a cytotoxicity detection kit (Promega, Madison, WI), or a FITC-
Annexin V Apoptosis Detection kit (BD Pharmingen, San Jose, CA),
according to the manufacturer’s protocols.
Western blot analysis
Cells were lysed in M2 buffer (20mM Tris at pH 7, 0.5% NP-40, 250mM
NaCl, 3mM EDTA, 3mM EGTA, 2mM DTT, 0.5mM PMSF, 20mM
β-glycerol phosphate, 1mM sodium vanadate, and 1 μgml−1 leupeptin).
Equal cell extracts were resolved by 12% SDS-PAGE and analyzed
by western blot using enhanced chemiluminescence (Amersham,
Piscataway, NJ).
Immunostaining
HaCaT, HeLa, and HEKn cells were incubated on chamber slides and
ﬁxed by cold acetone (10 seconds). Immunohistochemical staining
was performed using the avidin–biotin–peroxidase complex. For
immunoﬂuorescence, anti-phospho-MLKL was incubated overnight
at 4 °C(1:250), and FITC-conjugated secondary antibody (goat
anti-rabbit IgM, 1:500 dilution, Molecular Probes, Eugene, OR) was
incubated 1 hour at room temperature. Representative images were
taken by confocal microscope.
Measurement of intracellular ROS
Cells were incubated with 10 μM H2 DCFDA for 30 minutes before
the end of treatments. Increases in ﬂuorescence were measured by
FACS and by examination under a confocal microscope (Carl Zeiss
LSM710).
Lentiviral shRNA experiments
Short-hairpin RNA (shRNA) plasmids targeting hRIP3 mRNA
(NM_006871), mRIP3 mRNA (NM_019955), hMLKL mRNA
(NM_152649), hRIP1 (NM_003804.3), and non-targeting control
(NM_027088) were from Sigma-Aldrich. Lentiviral plasmids were
transfected into 293TN cells (System Biosciences, Mountain View,
CA). Pseudoviral particles were collected 2 days after the transfection
and infected into cells with polybrene (8 μgml−1). Infected cells
were puromycin selected 2 days after infection.
Statistics
Independent experiments were performed at least in triplicate.
Statistical signiﬁcance was evaluated in paired analyses using the
Mann–Whitney U-test (nonparametric), depending on the data
distribution. Data values are expressed as mean± SEM. Statistical
signiﬁcance was considered Po0.05.
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